11 results about "Beta-boswellic acid" patented technology

The application discloses a carbonyl reductase mutant, a combined enzyme and application of the combined enzyme in synthesis of S-configuration boselike, and belongs to the technical field of biological catalysis and pharmacy. The amino acid sequence of the wild-type carbonyl reductase mutant provided by the application is shown as SEQ ID NO:1, and the mutant is obtained by mutation of the wild-type carbonyl reductase, and the mutation mode is that F at the 147th position is mutated into L, V at the 163rd position is mutated into Y, L at the 176th position is mutated into E, and P at the 200th position is mutated into R. By using the mutant, a catalytic system is formed by combining the mutant with formic acid dehydrogenase (FDH), and optical pure S-configuration boselike can be efficiently and highly selectively prepared under high substrate concentration of 250-320 g / L, separation and purification problems caused by generation of a large amount of soluble by-products in catalysis of other combined enzymes are avoided, a post-treatment process is obviously simplified, and production cost and environmental burden are reduced.

The present invention discloses water-soluble 3-O-acetyl-11-keto-β-boswellic acid compositions comprising 3-O-acetyl-11-keto-β-boswellic acid in combination with a metal ion selected from potassium or sodium in the form of respective metal salt or complex or chelate; process for their preparation; methods of prevention, control and / or treatment of at least one disorder selected from muscle soreness, delayed-onset of muscle soreness (DOMS), muscles tenderness, muscle pain, muscle fatigue, muscle sprain, temporary loss of muscle strength and swelling in muscles.

Compositions are described including a synergistic combination of hydroxytyrosol and 3-0-acetyl-11-keto-B-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-0-acetyl-11-keto-B-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof. 20 25 20 28 75 23 A pr 2 02 5 2 4 4 2 0 6 7 4 . 1 : D C C 3 1 / 0 5 / 2 0 2 3 C O M P O S I T I O N S C O M P R I S I N G H Y D R O X Y T Y R O S O L A N D B O S W E L L I C A C I D 2 0 2 5 2 0 2 8 7 5 2 3 2 0 2 5 A p r A B S T R A C T

The invention provides an application of beta-masticinic acid in preparation of a medicine with a tumor immune microenvironment regulating effect. According to the new application of the beta-masticinic acid, the targeting property is clear, the beta-masticinic acid directly regulates and controls Kyn metabolism, the complexity of multiple components of the western huang pill is avoided, and quality control and dosage standardization are facilitated; in an in-vitro experiment, the beta-masticinic acid (100 mu M) has the most remarkable tumor cell proliferation inhibition effect, and the beta-masticinic acid (100 mu M) remarkably reduces the Kyn expression level of macrophages and remarkably enhances the expression of M1 type macrophages; the beta-masticinic acid can play a role in regulating a tumor immune microenvironment through an ERBB2 target spot; the safety is high: the beta-masticinic acid has an anti-tumor effect by regulating immune cells under an effective dose, while the traditional chemotherapeutic drug gemcitabine causes immune injury; the mechanism is novel, and it is found for the first time that beta-masticinic acid regulates the tumor immune microenvironment by influencing the expression of Kyn.

Provided are a crystalline form of a pentacyclic triterpenoid compound and a preparation method of the crystalline form, the pentacyclic triterpenoid compound being 3-O-cyclohexanecarbonyl-11-carbonyl-beta-boswellic acid, abbreviated as CKBA, the preparation method of the crystalline form being simple in operation, the crystalline form prepared being more stable under light conditions, less change in impurities, and the crystalline form prepared being higher in solubility in organic solvents, lower in hygroscopicity, and more conducive to development of a subsequent preparation process. Further provided are a pharmaceutical composition using the crystalline form as an active ingredient, and use of the crystalline form in preparation of a medicament for treating psoriasis.

A composition for use in the treatment of dermatoporosis, comprising: at least one boswellic acid, optionally in the form of a plant extract in a proportion of 0.1 to 15% by weight relative to the weight of the composition, a hyaluronan in a proportion of 0.1 to 15% by weight relative to the weight of the composition, said composition further having a proportion by weight of boswellic acid to hyaluronan of between 0.5 and 2 and an excipient phase in a proportion of 99.8% to 70% by weight relative to the weight of the composition, the excipient phase being aqueous-based.

To provide a natural product-derived composition that allows for the easy intake of nutrients that can exhibit excellent functionality. [Solution] The composition comprises a collagen-containing extract derived from fish cartilage and a boswellic acid-containing extract derived from the Boswellia plant. The collagen-containing extract preferably contains type II collagen and type XI collagen, with a total mass ratio of their contents being 10:1 to 1:10, and a total content of 30% by mass or more. The boswellic acid-containing extract preferably contains 20% by mass or more of boswellic acid.

The optimized drug delivery system, with a diameter of less than 150 nm, can cross the Blood-Brain Barrier (BBB) and effectively target brain cells. This all-natural herbal formulation contains Curcumin from Turmeric and Boswellic acids from Frankincense, encapsulated in a vesicular structure. The surface of vesicular structure has been modified and optimized for maximum bioavailability. This Nanocarrier is used for prevention of Alzheimer's disease and memory enhancement. Animal studies confirmed its effectiveness, showing positive results.

Composition or association of compounds comprising: a) the active principle docosahexaenoic acid DHA (C22:6 ω-3 C22H32O2 MW 328.488) mixed with all or in part, with: b) hyaluronic acid HA4 tetrasaccharide (C28H44N2O23 MW 776) in nanoparticles c) β-caryophyllene βCP (C15H24 MW 204.35), d) furanoeudesma-1,3-diene FE (C15H18O MW 214.30), e) β-boswellic acid PBA (C30H48O3 MW 456.7). preferably for use in the treatment of nervous diseases in particular neurodegenerative diseases, method for the preparation of such composition or association of compounds and uses thereof.

The invention relates to a method for preparing high-purity 3-acetyl-11-keto-beta-boswellic acid through high-speed countercurrent chromatography separation, which comprises the following steps: by taking commercially available frankincense extract as a raw material, fully shaking a solvent system, standing for phase separation, and separately collecting an upper phase and a lower phase; dissolving the frankincense extract in the upper phase, performing separation and purification by using high-speed counter-current chromatography to obtain a mixed solution of 3-acetyl-11-keto-beta-masticinic acid and the upper phase, removing the organic solvent in the upper phase to obtain a turbid liquid containing 3-acetyl-11-keto-beta-masticinic acid, and centrifuging to remove an aqueous solution to obtain the frankincense extract. And filtering to obtain the 3-acetyl-11-keto-beta-masticinic acid. The purity of the 3-acetyl-11-keto-beta-masticinic acid prepared by the method disclosed by the invention is up to 98% or above; reagents of a solvent system can be recycled and reused, and good energy-saving and environment-friendly functions are achieved.

This invention belongs to the field of nutritional composition technology, specifically relating to a composition, composition formulation, preparation method, application, and product for improving bone health. This invention provides a composition composed of N-acetylglucosamine and 3-O-acetyl-11-keto-β-boswellic acid. The composition and formulation of this invention can promote the differentiation of chondrocyte precursor cells into mature chondrocytes, promote cartilage matrix synthesis, significantly inhibit TNF-α and MMP13 expression, and upregulate COL2A1 expression, with effects superior to single components and traditional combinations. The ingredients are natural and safe, biocompatible, and have no significant toxicity, making them suitable for people with joint noise, joint pain, osteoarthritis, and joint degeneration. Simultaneously, they can improve bone density, promote bone growth and development, and improve bone health. The preparation process is simple and low-cost, and it can be formulated into various dosage forms such as food, health products, and pharmaceuticals, offering flexible applications and combining preventative and therapeutic value.